Terns Pharmaceuticals, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDTerns Pharmaceuticals, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings growth of 4% provides fundamental context to the price action. Investors should exercise caution due to high volatility (102% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $52.78 | +0.35% | ABOVE |
| 50 SMA | $49.21 | +7.63% | ABOVE |
| 100 SMA | $43.96 | +20.49% | ABOVE |
| 150 SMA | $34.76 | +52.39% | ABOVE |
| 200 SMA | $27.75 | +90.86% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TERN in an uptrend right now?
TERN has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, TERN is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is TERN overbought or oversold?
TERN's RSI (14) is 74. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is TERN outperforming the market?
TERN has a Relative Strength (RS) Rating of 98 out of 99. Yes, TERN is a market leader, outperforming 98% of all stocks over the past 12 months.
Where is TERN in its 52-week range?
TERN is trading at $52.97, which is 100% of its 52-week high ($53.18) and 100% above its 52-week low ($2.66).
How volatile is TERN?
TERN has a Beta of 0.39 and 52-week volatility of 102%. It's less volatile than the S&P 500 - generally more stable.